Company intelligence / Profile preview

Ratiopharm

Ulm, Baden-Württemberg, Germanyratiopharm.de ↗

Ownership: Private
Employees: ~4000
Development stage: Commercial

Overview

Ratiopharm has one of the widest product ranges in the generics business with about 750 medicines available exclusively from pharmacies. The company sells approximately 472 million pack units annually and meets needs across virtually all areas of medicine. Nearly 400 products are at the approval stage[5]. As a generics company, it does not conduct traditional clinical trials for new chemical entities but demonstrates bioequivalence to originator drugs.

Therapeutic areas: Other
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

cafedrine

Unknown

Partnerships

Founding member of Pro Generika association alongside Stada and Hexal for industry lobbying in Germany

Beyond the preview

Go deeper on Ratiopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ratiopharm.

Explore the full profile